Key Points
- Ari Maizel, an Axsome insider, sold 7,500 shares on January 21 at an average price of $184.44, generating $1.383 million, as disclosed in an SEC filing.
- Wall Street sentiment is broadly positive with multiple upgrades and higher targets (e.g., UBS $248, Piper Sandler $223) and a consensus "Moderate Buy" and $203.17 price target, supported by a potential Auvelity label expansion expected by April 30 that could materially expand the drug’s market.
- On fundamentals, Axsome missed quarterly EPS (‑$0.94 vs. estimate ‑$0.82) despite revenue rising 63% to $170.99 million; the company still shows negative margins and analysts forecast a -2.79 EPS for the fiscal year.
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) insider Ari Maizel sold 7,500 shares of the stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total value of $1,383,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Axsome Therapeutics Price Performance
Shares of NASDAQ AXSM opened at $185.96 on Friday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. Axsome Therapeutics, Inc. has a one year low of $86.99 and a one year high of $191.50. The firm has a market capitalization of $9.37 billion, a P/E ratio of -39.82, a PEG ratio of 9.86 and a beta of 0.44. The company's fifty day moving average is $159.39 and its two-hundred day moving average is $133.10.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The company had revenue of $170.99 million during the quarter, compared to analyst estimates of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The company's revenue for the quarter was up 63.2% compared to the same quarter last year. Analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Key Stories Impacting Axsome Therapeutics
Here are the key news stories impacting Axsome Therapeutics this week:
Wall Street Analysts Forecast Growth
Several research firms have recently commented on AXSM. UBS Group increased their price target on shares of Axsome Therapeutics from $163.00 to $248.00 and gave the company a "buy" rating in a research report on Tuesday, January 6th. Piper Sandler increased their target price on Axsome Therapeutics from $148.00 to $223.00 and gave the company an "overweight" rating in a report on Friday, January 16th. Robert W. Baird set a $209.00 price target on Axsome Therapeutics in a research report on Tuesday, January 13th. Morgan Stanley downgraded Axsome Therapeutics from an "overweight" rating to a "reduce" rating in a research report on Thursday, January 8th. Finally, TD Cowen reiterated a "buy" rating on shares of Axsome Therapeutics in a report on Wednesday, December 31st. Nineteen research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. According to MarketBeat, Axsome Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $203.17.
View Our Latest Stock Analysis on AXSM
Institutional Investors Weigh In On Axsome Therapeutics
Institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Axsome Therapeutics by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company's stock worth $2,557,000 after purchasing an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in shares of Axsome Therapeutics by 2,407.9% in the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company's stock valued at $889,000 after purchasing an additional 7,320 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Axsome Therapeutics by 38.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company's stock valued at $35,189,000 after buying an additional 84,151 shares during the period. Caxton Associates LLP acquired a new stake in shares of Axsome Therapeutics during the 1st quarter worth $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Axsome Therapeutics by 29.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company's stock worth $8,735,000 after buying an additional 17,250 shares during the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.
Axsome Therapeutics Company Profile
(
Get Free Report)
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome's pipeline includes several late-stage and approved product candidates.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
